A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System.

Odabassian M, Tsoukas MA, Cohen E, Pasqua MR, Rutkowski J, Haidar A

Journal of diabetes science and technology14 Oct 2025Cited by 1 (Europe PMC)

PMID41174925PMCIDPMC12678853DOI10.1177/19322968251371046PepBankPUB-41174925

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

01HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, faster aspart-pramlintide at the lower ratio did not significantly change time in range versus control.
In plain wordsIn adults with diabetes, faster aspart-pramlintide at the lower ratio did not significantly change time in range versus control.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTime in target range with faster aspart and pramlintide at 8 µg/U
Study
n = 12
Comparator
Faster aspart with carbohydrate counting
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median time in target range
78.6%
Control, faster aspart with carbohydrate counting
Median time in target range
76.2%
Faster aspart-pramlintide 8 µg/U
Source sentences
Summary
The median time in target range (3.9-10.0 mmol/L) with the control arm was 78.6 [65.3-92.9], compared with 76.2 [64.6-86.9] and 78.8 [68.8-86.0] with the fully closed-loop faster aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively,
2 context sentences(design, population, supporting numbers)
Summary · context
None of the differences were statistically significant.
Summary · context
We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-4117492501
02HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, faster aspart-pramlintide at the higher ratio did not significantly change time in range versus control.
In plain wordsIn adults with diabetes, faster aspart-pramlintide at the higher ratio did not significantly change time in range versus control.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTime in target range with faster aspart and pramlintide at 10 µg/U
Study
n = 12
Comparator
Faster aspart with carbohydrate counting
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median time in target range
78.6%
Control, faster aspart with carbohydrate counting
Median time in target range
78.8%
Faster aspart-pramlintide 10 µg/U
Source sentences
Summary
The median time in target range (3.9-10.0 mmol/L) with the control arm was 78.6 [65.3-92.9], compared with 76.2 [64.6-86.9] and 78.8 [68.8-86.0] with the fully closed-loop faster aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively,
2 context sentences(design, population, supporting numbers)
Summary · context
None of the differences were statistically significant.
Summary · context
We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-4117492502
03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, aspart-pramlintide at the lower ratio did not significantly change time in range versus control.
In plain wordsIn adults with diabetes, aspart-pramlintide at the lower ratio did not significantly change time in range versus control.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTime in target range with aspart and pramlintide at 8 µg/U
Study
n = 12
Comparator
Faster aspart with carbohydrate counting
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median time in target range
78.6%
Control, faster aspart with carbohydrate counting
Median time in target range
65.9%
Aspart-pramlintide 8 µg/U
Source sentences
Summary
The median time in target range (3.9-10.0 mmol/L) with the control arm was 78.6 [65.3-92.9]
Summary
and compared with 65.9 [59.9-83.6] and 77.4 [72.1-82.7] with the fully closed-loop aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
None of the differences were statistically significant.
Summary · context
We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-4117492503
04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, aspart-pramlintide at the higher ratio did not significantly change time in range versus control.
In plain wordsIn adults with diabetes, aspart-pramlintide at the higher ratio did not significantly change time in range versus control.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTime in target range with aspart and pramlintide at 10 µg/U
Study
n = 12
Comparator
Faster aspart with carbohydrate counting
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median time in target range
78.6%
Control, faster aspart with carbohydrate counting
Median time in target range
77.4%
Aspart-pramlintide 10 µg/U
Source sentences
Summary
The median time in target range (3.9-10.0 mmol/L) with the control arm was 78.6 [65.3-92.9]
Summary
and compared with 65.9 [59.9-83.6] and 77.4 [72.1-82.7] with the fully closed-loop aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
None of the differences were statistically significant.
Summary · context
We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-4117492504
05HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In adults with type 1 diabetes, aspart-pramlintide systems numerically increased time below 3.9 mmol/L versus control, without statistical significance.
In plain wordsIn adults with diabetes, aspart-pramlintide systems numerically increased low-glucose time versus control, without statistical significance.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTime below 3.9 mmol/L
Study
n = 12
Comparator
Faster aspart with carbohydrate counting
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Times spent below 3.9 and 3.0 mmol/L were numerically higher with the fully closed-loop aspart and pramlintide systems than the control arm.
2 context sentences(design, population, supporting numbers)
Summary · context
None of the differences were statistically significant.
Summary · context
We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-4117492505
06HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In adults with type 1 diabetes, aspart-pramlintide systems numerically increased time below 3.0 mmol/L versus control, without statistical significance.
In plain wordsIn adults with diabetes, aspart-pramlintide systems numerically increased very-low-glucose time versus control, without statistical significance.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTime below 3.0 mmol/L
Study
n = 12
Comparator
Faster aspart with carbohydrate counting
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Times spent below 3.9 and 3.0 mmol/L were numerically higher with the fully closed-loop aspart and pramlintide systems than the control arm.
2 context sentences(design, population, supporting numbers)
Summary · context
None of the differences were statistically significant.
Summary · context
We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-4117492506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.